Publication at Third Faculty of Medicine |
2018
Abstract
In the following text, we are discussing the case of a patient with non-small cell lung cancer, whom the presence of the actiwating mutation of the epidermal grow factor has been proved. We begun treatment with erlotinib in the first line until progression which apperaed on computed tomography after 15 months, in the second line treatment she received three cycles of the chemotherapy with pemetrexed.
The second line treatment was terminated due to progression and high hematoxicity. Following the patientś wishes, further steps regarding treatment are now in the competence of the regional oncologist.